Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Merck & Co. and Moderna have shared highly anticipated phase 3 data on their cancer vaccine, revealing a primary endpoint hit ...
Celltrion has licensed a preclinical antibody aimed at autoimmune conditions from Maryland-based biotech Kaigene in a deal ...
‘A two-way conversation with the tumor’: Researchers use ‘avatar’ to predict immunotherapy responses
Researchers are exploring a revolutionary way to predict a patient's response to immunotherapies by creating a tumor “avatar” ...
| GSK may have cemented its hepatitis B credentials with Tuesday’s landmark FDA nod for its “functional cure” bepirovirsen, ...
The FDA's Center for Biologics Evaluation and Research (CBER) is recovering from the most turbulent period in its recent ...
Reverse mergers have returned with a bang. More biotechs have taken this back door to the public markets so far in 2026 than ...
Hologic is acquiring precision oncology company Reveal Genomics. | Hologic is acquiring precision oncology company Reveal ...
The Society for Clinical Research Sites (SCRS) has launched a data intelligence platform to offer fresh insights into how ...
Lycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for ...
Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambition
Rapport Therapeutics’ phase 2 bipolar mania study has hit its primary endpoint, furthering the biotech’s efforts to make RAP-219 a multi-indication blockbuster. However, the effect size fell short of ...
Amid the Chinese biopharma licensing boom, Hengrui Pharmaceuticals stands out from the crowd. | Amid the Chinese biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results